Statin use associated with reduced risk of prostate cancer recurrence

May 2, 2014

(Medical Xpress)—Men who begin taking statins after prostate cancer surgery are less likely to have a recurrence of their cancer, according to a retrospective analysis led by researchers at Duke Medicine.

"Our findings suggest that beginning after surgery may reduce the risk of recurrence, so it's not too late to start statins after a diagnosis," said lead author Emma H. Allott, Ph.D., a postdoctoral associate in the Division of Urology at Duke and the Durham Veterans Affairs Medical Center.

A secondary analysis revealed that this protective association was only significant among non-black , although this possible racial disparity requires further investigation.

The study appears online in BJU International (formerly the British Journal of Urology).

Prostate cancer is the most common non-skin cancer in men, according to the American Cancer Society. For men with localized disease, radical prostatectomy – or surgery to remove the prostate – is a common treatment option. However, approximately 30 percent of men have a recurrence of their prostate cancer within 10 years of surgery.

Cholesterol-lowering statins are known to improve cardiovascular outcomes, but less is known about how statins impact cancer risk and progression. Previous meta-analyses examining the effect of statins on and progression have reported mixed results.

In lab studies of cells and tissue samples, cholesterol has been shown to promote prostate cancer growth, while lowering cholesterol slows prostate cancer growth and reduces inflammation.

"It is possible that statins could inhibit cancer growth through several mechanisms, either directly by inhibiting certain metabolic pathways, or indirectly by lowering cholesterol," said senior author Stephen J. Freedland, M.D., associate professor of urology and pathology at Duke and a urologist at the Durham Veterans Affairs Medical Center.

"Given how widely-prescribed statins are, and the biological plausibility of statins slowing , it is important for us to figure out how they may affect men with prostate cancer."

The researchers analyzed the medical records of men with prostate cancer who underwent radical prostatectomy. They chose to study men who had never used statins prior to surgery in order to test whether beginning statin therapy afterprimary treatment could influence , an important question in terms of translating findings to randomized controlled trials and ultimately to clinical practice.

During a median follow-up period of just over six years, cancer returned in 65 of the 400 men who began taking statins after surgery, and 337 of 746 men who never took statins. The researchers conducted a statistical analysis, taking into account the demographic and tumor characteristics of patients in addition to the duration of statin use during the follow-up period. They concluded that postoperative statin use was associated with a 36 percent reduced risk of prostate cancer recurrence.

In a secondary analysis, this protective association was found to be significant only among non-black men. While prior studies have shown race-specific differences in prostate cancer tumor biology, additional research is needed to better understand whether the association between statin use and recurrence differs by race.

Since the current study was retrospective and limited by the information recorded in medical records, the researchers stressed the importance of conducting randomized, controlled trials to assess the effect of postoperative statin use on prostate cancer recurrence.

"These future studies will help to determine whether statins – which are cost-effective and generally well-tolerated – may play a beneficial role in , in addition to their proven role in preventing cardiovascular mortality," Allott said.

Explore further: Blood clue to prostate cancer recurrence

Related Stories

Blood clue to prostate cancer recurrence

April 14, 2014
Men with blood group O are far less likely to suffer a recurrence of cancer after prostate tumour surgery than men with other blood types, researchers reported on Monday.

Cholesterol unlocks clues to prostate cancer spread

April 17, 2014
(Medical Xpress)—The findings could help explain why taking statins – commonly used cholesterol-lowering drugs – is thought to slow the progress of the disease in some cases.

Statin use linked to lower prostate cancer death risk

November 5, 2013
(HealthDay)—Prostate cancer patients who take the cholesterol-lowering drugs known as statins appear to face a lower risk of death from their disease, new Canadian research suggests.

Taking cholesterol-lowering drugs may also reduce the risk of dying from prostate cancer, study finds

May 2, 2013
Men with prostate cancer who take cholesterol-lowering drugs called statins are significantly less likely to die from their cancer than men who don't take such medication, according to study led by researchers at Fred Hutchinson ...

Cholesterol-lowering drugs may slow prostate growth

May 21, 2012
Statins drugs prescribed to treat high cholesterol may also work to slow prostate growth in men who have elevated PSA levels, according to an analysis led by researchers at Duke University Medical Center.

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.